US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.7200

-0.0058-0.80%

Post-market: 0.72540.0054+0.75%18:38 EDT

Volume:79.48K

Turnover:57.36K

Market Cap:24.03M

PE:-0.51

High:0.7400

Open:0.7053

Low:0.7053

Close:0.7258

52wk High:5.75

52wk Low:0.5655

Shares:33.38M

Float Shares:19.88M

Volume Ratio:0.53

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4100

EPS(LYR):-1.4100

ROE:-126.85%

ROA:-71.93%

PB:1.20

PE(LYR):-0.51

Loading ...

Overview Company News Filings

Skye Bioscience CEO presents nimacimab-GLP-1 obesity combination strategy at GLP-1 therapeutics summit

Skye Bioscience announces annual shareholder meeting via webcast

Skye Bioscience corrects option repricing share count to 2,458,158 shares

Skye Bioscience names John P. Sharp CFO

BUZZ-Skye Bioscience rises as it begins testing higher doses of obesity drug

Skye Bioscience doses first patient in higher-dose nimacimab Phase 2a expansion study

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2B Dose Selection for Glp-1 Combination Development

THOMSON REUTERS

Skye Bioscience Inc - Topline Data From Expansion Study Expected in Q4 2026

THOMSON REUTERS

Skye Bioscience investor presentation spotlights nimacimab-semaglutide combo weight-loss data

Skye Bioscience receives Nasdaq notice for SKYE bid price below $1 for 30 days

Skye Bioscience (SKYE) Receives a Hold from Cantor Fitzgerald

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF)

Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate

Skye Bioscience FY 2025 net loss rises 111% to USD 55.92 million

Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience Inc expected to post a loss of 30 cents a share - Earnings Preview

Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy

Skye Bioscience Inc. to Announce 2025 Financial Results and Business Update on Conference Call

Skye Bioscience Publishes Corporate Presentation on Nimacimab–Semaglutide Obesity Combination Strategy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SKYE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":0.72,"timestamp":1775851200000,"preClose":0.7258,"halted":0,"volume":79480,"hourTrading":{"tag":"盘后","latestPrice":0.7254,"preClose":0.72,"latestTime":"18:38 EDT","volume":1255,"amount":902.7207,"timestamp":1775860710557,"change":0.0054,"changeRate":0.0075,"amplitude":0.020139},"delay":0,"changeRate":-0.007991182143841317,"floatShares":19882200,"shares":33378764,"eps":-1.410011,"marketStatus":"Market Closed","change":-0.0058,"latestTime":"04-10 16:00:00 EDT","open":0.7053,"high":0.74,"low":0.7053,"amount":57360.1485128,"amplitude":0.047809,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.410011,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":0.7258,"preHourTrading":{"tag":"盘前","latestPrice":0.718,"preClose":0.7258,"latestTime":"09:15 EDT","volume":114,"amount":81.46900559999999,"timestamp":1775826907885,"change":-0.0078,"changeRate":-0.010747,"amplitude":0.009645},"postHourTrading":{"tag":"盘后","latestPrice":0.7254,"preClose":0.72,"latestTime":"18:38 EDT","volume":1255,"amount":902.7207,"timestamp":1775860710557,"change":0.0054,"changeRate":0.0075,"amplitude":0.020139},"volumeRatio":0.5277902093917642,"impliedVol":1.1162,"impliedVolPercentile":0.444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":19882200,"roa":"-71.93%","roe":"-126.85%","lyrEps":-1.410011,"volumeRatio":0.5277902093917642,"shares":33378764,"dividePrice":0,"high":0.74,"amplitude":0.047809,"preClose":0.7258,"low":0.7053,"week52Low":0.5655,"pbRate":"1.20","week52High":5.75,"institutionHeld":0,"latestPrice":0.72,"eps":-1.410011,"divideRate":0,"volume":79480,"delay":0,"ttmEps":-1.410011,"open":0.7053,"prevYearClose":0.7497,"prevWeekClose":0.698,"prevMonthClose":0.6146,"prevQuarterClose":0.6146,"fiveDayClose":0.698,"twentyDayClose":0.707,"sixtyDayClose":0.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-10","symbol":"SKYE","fiscalQuarterEnding":"2025/12","expectedEps":-0.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-07","symbol":"SKYE","fiscalQuarterEnding":"2025/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1759809600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2026-04-10","current":-0.510634,"percent":0.958592,"low":-12.94129,"twenty":-4.547475,"median":-2.991518,"eighty":-0.825125,"high":-0.344383,"avg":-3.375851,"sd":2.590263,"marketCap":24226306},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-19","current":-0.625701,"twenty":-4.9588,"median":-3.549105,"eighty":-1.981949,"marketCap":32054255},{"date":"2025-12-26","current":-0.522137,"twenty":-4.912548,"median":-3.544049,"eighty":-1.945365,"marketCap":26748745},{"date":"2026-01-02","current":-0.469135,"twenty":-4.89913,"median":-3.530125,"eighty":-1.880836,"marketCap":24033478},{"date":"2026-01-09","current":-0.657052,"twenty":-4.893905,"median":-3.501657,"eighty":-1.841207,"marketCap":33660334},{"date":"2026-01-16","current":-0.60236,"twenty":-4.863947,"median":-3.501004,"eighty":-1.780246,"marketCap":30858511},{"date":"2026-01-23","current":-0.657052,"twenty":-4.827714,"median":-3.463671,"eighty":-1.698098,"marketCap":33660334},{"date":"2026-01-30","current":-0.600733,"twenty":-4.820607,"median":-3.430485,"eighty":-1.632257,"marketCap":30775162},{"date":"2026-02-06","current":-0.500298,"twenty":-4.784865,"median":-3.387782,"eighty":-1.562303,"marketCap":25629940},{"date":"2026-02-13","current":-0.451176,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"marketCap":23113429},{"date":"2026-02-20","current":-0.488221,"twenty":-4.650603,"median":-3.310888,"eighty":-1.249103,"marketCap":25011231},{"date":"2026-02-27","current":-0.482464,"twenty":-4.611231,"median":-3.270848,"eighty":-1.139404,"marketCap":24716302},{"date":"2026-03-06","current":-0.461814,"twenty":-4.588626,"median":-3.232166,"eighty":-1.117465,"marketCap":23658406},{"date":"2026-03-13","current":-0.421973,"twenty":-4.584426,"median":-3.115445,"eighty":-1.099913,"marketCap":23598786},{"date":"2026-03-20","current":-0.391057,"twenty":-4.563756,"median":-3.07414,"eighty":-1.060422,"marketCap":21869766},{"date":"2026-03-27","current":-0.368854,"twenty":-4.556212,"median":-3.020373,"eighty":-1.032631,"marketCap":20628076},{"date":"2026-04-02","current":-0.396846,"twenty":-4.55561,"median":-3.01306,"eighty":-0.904924,"marketCap":22193540},{"date":"2026-04-10","current":-0.433194,"twenty":-4.547475,"median":-2.991518,"eighty":-0.825125,"marketCap":24226306}],"updateTime":1775903902838},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625932669","title":"Skye Bioscience CEO presents nimacimab-GLP-1 obesity combination strategy at GLP-1 therapeutics summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932669","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932669?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:04","pubTimestamp":1775559869,"startTime":"0","endTime":"0","summary":"Skye Bioscience to present at GLP-1-Based Therapeutics Summit in Boston, April 14-16, 2026.CEO Punit Dhillon scheduled to speak April 16, 2026 at 1:30 pm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6hJJn9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2625601881","title":"Skye Bioscience announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601881","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601881?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:16","pubTimestamp":1775506606,"startTime":"0","endTime":"0","summary":"Skye Bioscience will hold 2026 annual stockholder meeting via virtual internet webcast on [ ].Shareholders will vote to elect six director nominees for one-year terms expiring at 2027 annual meeting.Investors will also vote on amendment to increase authorized common shares to 300,000,000 from 100,000,000.Meeting agenda includes advisory vote on named executive officer compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLSLxn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625609784","title":"Skye Bioscience corrects option repricing share count to 2,458,158 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2625609784","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625609784?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:11","pubTimestamp":1775506288,"startTime":"0","endTime":"0","summary":"Skye Bioscience filed an amended Form 8-K to correct an error in its April 3, 2026 report on an option repricing.Amendment updates total common shares underlying repriced options to 2,458,158.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL4dG4Cg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624644936","title":"Skye Bioscience names John P. Sharp CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2624644936","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624644936?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:47","pubTimestamp":1775249279,"startTime":"0","endTime":"0","summary":"Skye Bioscience appointed John P. Sharp as chief financial officer, effective March 31, 2026.Sharp currently serves as senior director at Lohman & Associates.His prior CFO roles include SaNOtize Research and Development Corp. and PhaseBio Pharmaceuticals.Skye Bioscience also repriced employee stock options granted before Dec. 31, 2025, cutting exercise prices to $0.615 per share.Options covering 2,420,978 shares were repriced, including 1,103,959 options held by CEO Punit Dhillon and 396,295 held by COO Tuan Diep.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL28ZNhs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624052725","title":"BUZZ-Skye Bioscience rises as it begins testing higher doses of obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2624052725","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624052725?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:45","pubTimestamp":1775130329,"startTime":"0","endTime":"0","summary":"BUZZ-Skye Bioscience rises as it begins testing higher doses of obesity drug** Shares of biotech firm Skye Bioscience SKYE.O rise 1.2% to $0.67 premarket** Co says it has begun testing higher doses of its experimental obesity drug, nimacimab, in a new expansion study ** Adds the study will test 400 mg and 600 mg intravenous doses over 16 weeks to check safety and how the drug moves through the body, versus placebo** Eight patients will be enrolled per dose group; the second group will start only if no safety issues emerge after four weeks - SKYE** Earlier data showed a combination of nimacimab and semaglutide led to 22.3% average weight loss after 52 weeks, with no plateau - SKYE** Co plans to report early data in Q4 this year and will refine upcoming trials after FDA feedback** As of last close, stock down ~11% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503686","title":"Skye Bioscience doses first patient in higher-dose nimacimab Phase 2a expansion study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503686","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503686?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:04","pubTimestamp":1775127860,"startTime":"0","endTime":"0","summary":"Skye Bioscience treated first patient in Part C expansion of Phase 2a CBeyond trial to test higher-dose IV nimacimab exposure over 16 weeks.Study will compare 400 mg IV or 600 mg IV weekly dosing versus placebo to benchmark safety profile for potential use with GLP-1 therapies.Escalation to 600 mg cohort depends on independent safety review following first participants completing four weeks in 400 mg cohort.Program builds on prior CBeyond results already presented from nimacimab with semaglutide, which showed sustained weight loss with tolerability profile that supported continued development.Topline Part C data will be reported in Q4 2026 to guide Phase 2b dose selection and trial design discussions with FDA.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL6NPF0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SKYE","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","NDAQ","BK4588","BK4585","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503356","title":"Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2B Dose Selection for Glp-1 Combination Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503356?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:00","pubTimestamp":1775127619,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503339","title":"Skye Bioscience Inc - Topline Data From Expansion Study Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503339?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:00","pubTimestamp":1775127619,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0FA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624545104","title":"Skye Bioscience investor presentation spotlights nimacimab-semaglutide combo weight-loss data","url":"https://stock-news.laohu8.com/highlight/detail?id=2624545104","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624545104?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:33","pubTimestamp":1775068420,"startTime":"0","endTime":"0","summary":"Skye Bioscience outlined a development plan for nimacimab, a peripherally restricted CB1-inhibiting antibody, as an add-on to GLP-1 therapy for obesity.CBeyond combination data showed 22.3% mean weight loss at 52 weeks with no plateau observed.At 26 weeks, nimacimab delivered 3.0% incremental weight loss versus semaglutide alone.Safety update cited 0 nimacimab-associated neuropsychiatric signal through 52 weeks.Skye flagged a dosing shift as 200 mg weekly monotherapy was underexposed in peripheral tissues; higher-dose expansion study underway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL9vT9vf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620627173","title":"Skye Bioscience receives Nasdaq notice for SKYE bid price below $1 for 30 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2620627173","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620627173?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:20","pubTimestamp":1773955220,"startTime":"0","endTime":"0","summary":"Skye received a Nasdaq notice stating its common stock bid price had closed below $1 for 30 consecutive business days, breaching Nasdaq Listing Rule 5450.The company has until September 14, 2026 to regain compliance, and it can do so if the bid price closes at $1 or more for at least 10 consecutive business days.A reverse stock split is one option, but it would need to be completed no later than 10 business days before September 14, 2026.If compliance is not regained by that deadline, Skye may be eligible for an additional 180-day period if it meets other Nasdaq Capital Market listing standards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2Vp0Vx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928481","title":"Skye Bioscience (SKYE) Receives a Hold from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928481?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:27","pubTimestamp":1773235640,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Skye Bioscience yesterday and set a price target of $2.00. The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-hold-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-hold-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912400","title":"Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912400?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Skye Bioscience (SKYE – Research Report) and Sando...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-sandoz-group-ltd-othersdzxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-sandoz-group-ltd-othersdzxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","SKYE","BK4588","LU0029874061.USD","XBI","BK4585","BK4581","BK4139","XLV","LABU","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618696141","title":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618696141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618696141?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:01","pubTimestamp":1773176475,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings SummarySkye Bioscience Inc SKYE.OQ reported a quarterly adjusted loss of 36 cents per share for the quarter ended Decem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY2N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618966184","title":"Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966184","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966184?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:02","pubTimestamp":1773172933,"startTime":"0","endTime":"0","summary":"Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 21.21 percent. This is a 50 percent decrease over losses of $(0.24) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51172692/skye-bioscience-q4-eps-0-36-misses-0-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618669539","title":"Skye Bioscience FY 2025 net loss rises 111% to USD 55.92 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618669539","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618669539?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:01","pubTimestamp":1773172913,"startTime":"0","endTime":"0","summary":"Skye Bioscience reported a Q4 net loss of USD 14.44 million, widening 48%, and R&D expenses of USD 11.47 million, up 47% mainly due to contracted manufacturing costs tied to anticipated Phase 2b supply and employee-related benefits. For FY 2025, net loss widened to USD 55.92 million and R&D expenses more than doubled to USD 42.36 million, driven primarily by contracted clinical study and manufacturing costs for nimacimab and increased discovery research and compensation. Cash, cash equivalents and short-term investments were USD 25.7 million at year-end, and Skye said this is expected to fund operations and key clinical milestones through Q4 2026, excluding the anticipated clinical cost of a proposed Phase 2b trial and additional manufacturing to supply such a study. Skye said it initiated the CBeyond Expansion Study  with 400 mg and 600 mg IV weekly nimacimab monotherapy cohorts versus placebo over 15 weeks, and expects topline data in Q4 2026. CEO Punit Dhillon said CBeyond showed a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL6CnrV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","BK4139","BK4112","SKYE","BK4585","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618966955","title":"Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966955?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:01","pubTimestamp":1773172860,"startTime":"0","endTime":"0","summary":"-- Initiated higher-dose CBeyond Expansion Study  to generate. higher-exposure human safety and pharmacokinetic data with 400 mg and 600. -- Received written FDA Type C meeting minutes; feedback is informing key. Phase 2b combination design elements and the Company's ongoing evaluation. of a potential add-on development path with incretin therapy;-- Presented new body composition data demonstrating differentiated weight. maintenance profile for patients that have discontinued combination. conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA. SAN DIEGO, March 10, 2026  -- Skye Bioscience, Inc.  , a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.-- Initiated the Expansion Study of CBeyond to ass","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1066051811.HKD","LU1066053197.SGD","LU2237443382.USD","LU2456880835.USD","LU0314104364.USD","LU2417539215.USD","BK4214","LU1674673691.USD","R","LU0786609619.USD","LU0882574139.USD","LU1366333091.USD","LU1066051225.USD","LU1718418525.SGD","LU0149725797.USD","LU1778281490.HKD","LU2237443622.USD","LU2083900584.USD","LU2236285917.USD","LU1066051498.USD","LU1674673428.USD","LU1935043023.USD","BK4022","LU2237443549.SGD","LU1935042991.SGD","LU0053666078.USD","LU0157215616.USD","LU1935042215.USD","LU1935042488.USD","LU2420271590.USD","SKYE","LU0170899867.USD","LU1366192091.USD","APC","BK4232","LU2237443978.SGD","LU1935043536.SGD","LU1496350171.SGD","LU0077335932.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617020637","title":"Skye Bioscience Inc  expected to post a loss of 30 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617020637","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617020637?lang=en_us&edition=fundamental","pubTime":"2026-03-07 04:05","pubTimestamp":1772827506,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of30cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU2GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617754170","title":"Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2617754170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617754170?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:09","pubTimestamp":1772712583,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbTZ46y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617549541","title":"Skye Bioscience Inc. to Announce 2025 Financial Results and Business Update on Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549541","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617549541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712057,"startTime":"0","endTime":"0","summary":"Skye Bioscience will announce its 2025 fourth quarter and full-year financial results on March 10, 2026, with an earnings press release issued after the market closes and made available on the Investor Relations website. Skye Bioscience will host a conference call on March 10, 2026 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and provide a business update; the live webcast can be accessed via the Investor Relations website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbN0VMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","BK4112","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014005.SGD","SKYE","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613422381","title":"Skye Bioscience Publishes Corporate Presentation on Nimacimab–Semaglutide Obesity Combination Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2613422381","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613422381?lang=en_us&edition=fundamental","pubTime":"2026-02-22 09:32","pubTimestamp":1771723950,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. released a corporate presentation highlighting its obesity and metabolic disease program centered on nimacimab, a peripherally restricted CB1-inhibiting antibody, including development plans for use in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13% weight loss at 26 weeks for nimacimab plus semaglutide versus semaglutide alone , and interim extension data indicating 22.3% total weight loss at 52 weeks in the combination group with no plateau observed. It also reports reduced post-treatment weight rebound over a 13-week off-therapy follow-up  and notes tolerability observations in the combination arm, including no additive gastrointestinal burden and no neuropsychiatric adverse events reported. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL1nTf1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}